Clinical Study
Effect of HSV-2 Suppressive Therapy on Genital Tract HIV-1 RNA Shedding among Women on HAART: A Pilot Randomized Controlled Trial
Table 2
Cumulative frequencies of clinical characteristics (visits 1–12).
| | Acyclovir ( visits) | No acyclovir ( visits) | Overall ( visits) |
| | Trichomonas | 1 (0.3%) | 6 (2%) | 7 (1%) | | Candida | 29 (9%) | 29 (10%) | 58 (10%) | | Bacterial vaginosis | 104 (33%) | 76 (26%) | 180 (30%) | | Semen detected | 19 (6%) | 11 (4%) | 30 (5%) | | >100 GT leukocytes | 133 (42%) | 153 (52%) | 286 (47%) | | Detectable asymptomatic HSV | 10 (3%) | 30 (10%) | 40 (6%) | | Detectable PVL | 56 (18%) | 26 (9%) | 83 (14%) | | Detectable GT HIV | 40 (12%) | 28 (9%) | 68 (11%) | | Missed ≥ 1 ARV dose in 2 wk | 61 (19%) | 61 (20%) | 122 (20%) | | Missed ≥1 Acyclovir dose in 2 wk | 88 (31%) | N/A | N/A |
|
|
NOTE. GT, Genital Tract; HSV, herpes simplex virus; PVL, plasma viral load; ARV, antiretroviral.
|
